Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.06B P/E - EPS this Y 241.00% Ern Qtrly Grth -
Income 169.95M Forward P/E -7.90 EPS next Y -169.40% 50D Avg Chg -24.00%
Sales 319.12M PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 4.42 EPS next 5Y - 52W High Chg -38.00%
Recommedations 1.70 Quick Ratio 13.60 Shares Outstanding 58.90M 52W Low Chg 157.00%
Insider Own 1.18% ROA 20.35% Shares Float 43.68M Beta 2.17
Inst Own 102.36% ROE 40.69% Shares Shorted/Prior 3.23M/3.10M Price 18.57
Gross Margin 100.00% Profit Margin 53.26% Avg. Volume 1,152,187 Target Price 52.71
Oper. Margin -930.96% Earnings Date Oct 31 Volume 455,693 Change -2.37%
About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc. News
11/21/24 Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
11/19/24 Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
11/18/24 Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
11/13/24 Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
11/07/24 Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Protagonist Therapeutics: Q3 Earnings Snapshot
11/07/24 Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/05/24 Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
10/18/24 Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
10/16/24 State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc
09/10/24 Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
09/09/24 Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years
09/03/24 Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
08/06/24 Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
08/06/24 Protagonist Therapeutics: Q2 Earnings Snapshot
08/06/24 Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/01/24 RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
08/01/24 Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
07/31/24 Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
06:00 AM Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
PTGX Chatroom

User Image Capitulation_0 Posted - 18 hours ago

$SGMO BP's have too many choices and are confused which company to take out. lol . $TGTX, $PTGX, $IMCR

User Image Capitulation_0 Posted - 18 hours ago

$TGTX $PTGX bouncing towards their high.

User Image tttggg Posted - 1 day ago

@moneyspirit from x Couple more thoughts on $PTGX: Caught up with management yesterday and asked them what the goal is for obesity. I'm interested in that TA, because there's obviously little no nothing in the stock for it today, but it could be a big source of upside optionality if they can tell a believable story next year. The overarching idea is that none of the currently available oral peptides (including semaglutide and the $VKTX molecule) have been optimized for oral delivery. We have excellent data from $VKTX proving best in class tolerability and efficacy - but there are a lot of questions around required CAPEX/COGS to treat patients with >40mg/day in such a large (and outside of the US low price) indication.

User Image tttggg Posted - 1 day ago

$VKTX via @Biohazard3737 x.com Couple more thoughts on $PTGX: Caught up with management yesterday and asked them what the goal is for obesity. I'm interested in that TA, because there's obviously little no nothing in the stock for it today, but it could be a big source of upside optionality if they can tell a believable story next year. The overarching idea is that none of the currently available oral peptides (including semaglutide and the $VKTX molecule) have been optimized for oral delivery. We have excellent data from $VKTX proving best in class tolerability and efficacy - but there are a lot of questions around required CAPEX/COGS to treat patients with >40mg/day in such a large (and outside of the US low price) indication.

User Image david999957 Posted - 2 days ago

$PTGX Algo ran stops on FUD. I bought each dollar down thank you.

User Image VrtcIl Posted - 2 days ago

What are your targets on $PTGX? Closest round level at 38. Take out profits right before those round numbers. Many orders on those levels are waiting to get filled. Price: 37.28 Float: 54.2M Short Float: 5.4 % 💰 Dollar Volume: 826.8K ℹī¸ USA | Biotechnology

User Image Capitulation_0 Posted - 2 days ago

$PTGX oral

User Image Capitulation_0 Posted - 2 days ago

$PTGX You mean to tell me fundamentals are at work here?

User Image OpenOutcrier Posted - 2 days ago

$PTGX (-3.9% pre) Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113) in plaque psoriasis, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor https://ooc.bz/l/48607

User Image Epawlow8 Posted - 1 week ago

$PTGX Moving north on readouts ahead

User Image 50bps Posted - 2 weeks ago

$PTGX anyone have proper earnings date on this, seeing a lot of noise?

User Image 50bps Posted - 10/31/24

$PTGX 👀

User Image StockConsultant Posted - 10/25/24

$PTGX Protagonist Therapeutics stock watch for a range breakout above 48.24 at https://stockconsultant.com/?PTGX

User Image Quantumup Posted - 1 month ago

TD Cowen reiterated $PTGX Buy/$65. TD Cowen said in its research note: We hosted meetings with Protagonist management to discuss the Q4 Phase III data in PsO, where the 200mg QD dose was clearly the best choice and 2113 could address at least 2M patients. UC is the main focus of investors, and 2113 does not need to beat injectables. Rusfertide can address a multi-billion dollar market, too. Oral IL-17 and obesity assets could also generate excitement and upside. $JNJ $tak

User Image Americanbulls Posted - 1 month ago

$PTGX the bull pattern is confirmed & a BUY signal is issued @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=PTGX. Buy Level: 44.58 Target: 85.15

User Image hick0ry2 Posted - 1 month ago

$PTGX

User Image hick0ry2 Posted - 1 month ago

$PTGX 👀

User Image Americanbulls Posted - 1 month ago

$PTGX may go up 91% if the bull pattern is confirmed. Check confirmation [40%] @ www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=PTGX. Buy level:44.18.

User Image DonCorleone77 Posted - 09/24/24

$PINS $GEV $SIRI $DAY $PTGX TOP 5 ANALYST INITIATIONS: -- Oppenheimer initiated coverage of Pinterest (PINS) with an Outperform rating and $45 price target. The firm says the company is the fastest-growing digital advertising platform excluding Meta Platforms (META). -- Guggenheim initiated coverage of GE Vernova (GEV) with a Buy rating and $300 price target. The firm forecasts gas turbine growth as electricity demand rises in the U.S., both in the "near term as growing service revenues" and "over the longer term as additional equipment revenue as bookings translate to revenue several years out," calling GE Verona "an attractive way for investors to participate in electricity load growth in the U.S." -- Morgan Stanley resumed coverage of Sirius XM (SIRI) with an Underweight rating and $23 price target. The firm sees continued risk to subscriber growth expectations. -- KeyBanc initiated coverage of Dayforce (DAY) with an Overweight rating and $70 price target. The firm believes Dayforce is well positioned to continue driving share gains in human capital management against legacy and point-solution providers in its core mid-market segment, as well as in enterprise as it continues to strengthen its international capabilities. -- TD Cowen initiated coverage of Protagonist Therapeutics (PTGX) with a Buy rating and $65 price target. The firm says the company's rusfertide has at least $3B of sales potential in polycythemia vera, with $1B going to Protagonist, and JNJ-2113 can address the 5M plaque psoriasis and ulcerative colitis patients seeking an oral option.

User Image F15EAGLE1 Posted - 1 month ago

$PTGX

User Image F15EAGLE1 Posted - 2 months ago

$PTGX

User Image CH_Expat Posted - 2 months ago

$PTGX Very glad I never bought in.

User Image brunjet Posted - 2 months ago

$PTGX approaching all time High

User Image Shlobby Posted - 2 months ago

$ptgx cc @Doozio to look at perfection

User Image 30DeltaSpy Posted - 2 months ago

$PTGX price target $60

User Image MortonMattD Posted - 2 months ago

$PTGX has been trending lately. Does it have the legs to keep going?

User Image Skrumpa Posted - 2 months ago

$PTGX Long at 43.10 Stop 42.11

User Image brunjet Posted - 08/28/24

$PTGX there it is. Past the 52 week high letsgooooo

User Image Master_of_Fine_Charts Posted - 08/27/24

RELATIVE STRENGTH SCREEN: $PTGX $REAX $BRFS $GLD https://www.chartmill.com/stock/stock-screener?f=v1_50b500,sl_crs_80_X,h13rs_nn52w,sm10v_a_sm20v,sm50v_a_sm150v,em13wv_r,em26wv_r,cu_a_sm200v,mc_smp,sl_se_7_X,sl_ta_7_X,sm5v_a_sm10v,adx_r,adx_a_20,exch_us&a=92899

User Image techj2022 Posted - 3 months ago

$PTGX 52 wk high in sight. weekly candle looks highly constructive. $xbi

Analyst Ratings
TD Cowen Buy Sep 24, 24
HC Wainwright & Co. Buy Sep 12, 24
Truist Securities Buy Sep 9, 24
JMP Securities Market Outperform Aug 7, 24
HC Wainwright & Co. Buy Aug 7, 24
JP Morgan Overweight Jul 25, 24
BTIG Buy Jul 24, 24
JMP Securities Market Outperform Jun 17, 24
HC Wainwright & Co. Buy Jun 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gupta Suneel Chief Development Of.. Chief Development Officer Jan 09 Sell 25 5,000 125,000 187,567 01/11/24
Gupta Suneel Chief Development Of.. Chief Development Officer Jan 09 Option 7.38 5,000 36,900 192,567 01/11/24
MOLINA ARTURO MD Chief Medical Office.. Chief Medical Officer Nov 15 Sell 16.24 1,848 30,012 22,527 01/04/24
Gupta Suneel Chief Development Of.. Chief Development Officer Oct 19 Option 7.38 20,000 147,600 168,317 10/23/23
PATEL DINESH V PH D President and CEO President and CEO Oct 18 Option 4.21 6,000 25,260 609,347 10/19/23
SELICK HAROLD E Director Director Apr 10 Option 0.87 6,196 5,391 21,506 04/11/23
PATEL DINESH V PH D President and CEO President and CEO Aug 23 Option 4.21 20,000 84,200 604,048 08/24/22
Waddill William D. Director Director May 03 Option 8.59 12,000 103,080 12,000 05/04/22
PATEL DINESH V PH D President and CEO President and CEO May 04 Option 4.21 15,742 66,274 584,048 05/04/22
Gupta Suneel Chief Development Of.. Chief Development Officer Apr 26 Option 7.38 40,000 295,200 117,561 04/26/22
PATEL DINESH V PH D President and CEO President and CEO Apr 26 Option 4.21 30,000 126,300 568,306 04/26/22
PATEL DINESH V PH D President and CEO President and CEO Apr 14 Option 1.89 34,087 64,424 537,847 04/14/22
Liu David Y Chief Scientific Off.. Chief Scientific Officer Aug 19 Sell 47.56 14,779 702,889 58,254 08/19/21
Liu David Y Chief Scientific Off.. Chief Scientific Officer Aug 19 Option 0.87 10,000 8,700 73,033 08/19/21